» Articles » PMID: 1435880

Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1992 Nov 26
PMID 1435880
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parkinson's disease is characterized by the loss of midbrain dopamine neurons that innervate the caudate and the putamen. Studies in animals suggest that fetal dopaminergic neurons can survive transplantation and restore neurologic function. This report compares the clinical results in four case patients with severe Parkinson's disease who underwent stereotaxic implantation of human fetal ventral mesencephalic tissue in one caudate nucleus with the results in a control group of similar subjects assigned at random to a one-year delay in surgery.

Methods: Each case patient received cryopreserved tissue from one fetal cadaver (gestational age, 7 to 11 weeks). Before implantation, adjacent midbrain tissue underwent microbiologic, biochemical, and viability testing. Cyclosporine was administered for six months postoperatively.

Results: The procedure was well tolerated. Three case patients showed bilateral improvement on motor tasks, as assessed on videotape, and were more functional in the activities of daily living, as assessed by themselves and neurologists, during both optimal drug therapy and "drug holiday" periods. One case patient, who died after four months from continued disease progression, had striatonigral degeneration at autopsy. In the patients who received transplants, optimal control was achieved with a lower dose of antiparkinsonian medications, whereas the controls required more medication. Positron-emission tomography with [18F]fluorodopa before and after surgery in one patient revealed a bilateral restoration of caudate dopamine synthesis to the range of normal controls, but continued bilateral deficits in the putamen.

Conclusions: Although the case patients continued to be disabled by their disease, unilateral intracaudate grafts of fetal tissue containing dopamine diminished the symptoms and signs of parkinsonism during 18 months of evaluation.

Citing Articles

Cell therapy for neurological disorders.

Svendsen S, Svendsen C Nat Med. 2024; 30(10):2756-2770.

PMID: 39407034 DOI: 10.1038/s41591-024-03281-3.


Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune responses.

Park T, Jeon J, Cha Y, Kim K Cell Res. 2024; 34(7):479-492.

PMID: 38777859 PMC: 11217403. DOI: 10.1038/s41422-024-00971-y.


Cell reprogramming therapy for Parkinson's disease.

Dong W, Liu S, Li S, Wang Z Neural Regen Res. 2024; 19(11):2444-2455.

PMID: 38526281 PMC: 11090434. DOI: 10.4103/1673-5374.390965.


Cell Replacement Therapy for Brain Repair: Recent Progress and Remaining Challenges for Treating Parkinson's Disease and Cortical Injury.

Harary P, Jgamadze D, Kim J, Wolf J, Song H, Ming G Brain Sci. 2023; 13(12).

PMID: 38137103 PMC: 10741697. DOI: 10.3390/brainsci13121654.


Unravelling the Parkinson's puzzle, from medications and surgery to stem cells and genes: a comprehensive review of current and future management strategies.

Chandrababu K, Radhakrishnan V, Anjana A, Rajan R, Sivan U, Krishnan S Exp Brain Res. 2023; 242(1):1-23.

PMID: 38015243 DOI: 10.1007/s00221-023-06735-1.